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Validation of a New HPLC Method for Determination of Midazolam and
its Metabolites: Application to Determine its Pharmacokinetics in Human
and Measure Hepatic CYP3A Activity in Rabbits
Abstract
Midazolam (MDZ) is a commonly used Benzodiazepine in clinical practice. In addition, its metabolic
oxidation is used as a surrogate marker for Cytochrome P450 (CYP) 3A enzyme activity as well. Thus, a new
simpler method to measure MDZ and its metabolites is welcomed. Herein we report a new and simple HPLC
method with ultraviolet detection for the simultaneous determination of midazolam and its hydroxyl
metabolites using lorazepam as an internal standard. A liquid-liquid extraction was used to extract the
compounds from rabbit hepatic microsomes and human plasma. The separation was performed on a Zorbax
Eclipse XDB C18 column using a mobile phase composed of 0.05M Na2PO4 (pH 4.5) and acetonitrile
mixture (67:33) pumped at 1.2 mL/min. The calibration curves showed good linearity with correlation
coefficient higher than 0.999 for all analytes in the range 10-500 ng/mL. Accuracy in the measurement of
quality control (QC) samples was in the range 95-106% of the nominal values. The intra-day and inter-day
precision in the measurement of QC samples were less than 11% coefficient of variation. Although less
sensitive than gas-chromatography-mass spectrometry (GC-MS), the proposed method was adequately
sensitive to measure midazolam hydroxylase activity as a marker for CYP3A activity, and was applied to
measure midazolam pharmacokinetics in human plasma.
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Validation of a New HPLC Method for Determination of Midazolam and its Metabolites: Application to Determine its 
Pharmacokinetics in Human and Measure Hepatic CYP3A Activity in Rabbits 
Fawzy Elbarbry a, Ahmed Attia b, Ahmed Shoker b
a Pacific University School of Pharmacy – College of Health Professions - Hillsboro, Oregon, USA
b Department of Medicine, University of Saskatchewan, Saskatoon, Canada
ABSTRACT
Midazolam (MDZ) is a commonly used Benzodiazepine in clinical practice.  In addition, its metabolic oxidation is used as a surrogate marker for Cytochrome P450 (CYP) 3A enzyme activity as well.  Thus, a new simpler method to measure MDZ and its metabolites is welcomed.  Herein we report a new and 
simple HPLC method with ultraviolet detection for the simultaneous determination of midazolam and its hydroxyl metabolites using lorazepam as an internal standard.  A liquid-liquid extraction was used to extract the compounds from rabbit hepatic microsomes and human plasma.  The separation was 
performed on a Zorbax Eclipse XDB C18 column using a mobile phase composed of 0.05M Na2PO4 (pH 4.5) and acetonitrile mixture (67:33) pumped at 1.2 mL/min.  The calibration curves showed good linearity with correlation coefficient higher than 0.999 for all analytes in the range 10-500 ng/mL.  Accuracy 
in the measurement of quality control (QC) samples was in the range 95-106% of the nominal values.  The intra-day and inter-day precision in the measurement of QC samples were less than 11% coefficient of variation.  Although less sensitive than gas-chromatography-mass spectrometry (GC-MS), the 
proposed method was adequately sensitive to measure midazolam hydroxylase activity as a marker for CYP3A activity, and was applied to measure midazolam pharmacokinetics in human plasma.. 
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HPLC
INSTRUMENTATION
The HPLC system consisted of Waters model 2695 Alliance 
separation module, model 2996 photodiode array detector and 
Empower data module (Millipore-Waters, Milford, MA, USA).  
Chromatographic separation was carried out on Zorbax Eclipse 
XDB C18 column (150 
 
4.6 mm I.D., 5 m particle size). The 
column was kept at 25°C. 
CHROMATOGRAPHIC CONDITIONS
The isocratic mobile phase consisted of 0.05M Na2 PO4 (pH 4.5) 
adjusted with phosphoric acid) and acetonitrile mixture (67:33) 
was run at a flow rate of 1.2 ml/min.  Absorbance was monitored 
at 227 nm. This wavelength was found adequate to monitor MDZ, 
1-OH MDZ, 4-OH MDZ, and LOR as indicated by using the PDA 
detector.
METHOD VALIDATION
Method validation procedures were performed according to FDA 
guidelines (www.fda.gov/cder/guidance/cmc3.pdf, accessed on 
Feb 10, 2009) to evaluate the suitability of the method for the 
quantitative determination of MDZ and its metabolites in rabbit 
hepatic microsomes and MDZ alone in human plasma. 
MEASUREMENT OF HEPATIC CYP3A ACTIVITY IN RABBITS
MDZ hydroxylase activity was determined by quantification of 1- 
OH MDZ and 4-OH MDZ formation rates in rabbit hepatic 
microsomes.  Preliminary experiments were conducted to 
determine linear metabolite formation kinetics with respect to 
MDZ concentration, incubation time and microsomal protein 
concentration. 
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Figure 1:  Typical HPLC chromatograms of MDZ and its metabolites in human plasma or rabbit hepatic microsomes 
samples. (a) Blank rabbit hepatic microsomes sample spiked with internal standard (LOR), 4-OH MDZ (200 ng/mL), 1-OH 
MDZ (200 ng/mL), and MDZ (200 ng/mL). (b) Blank human plasma sample spiked only with the internal standard (20µg/mL) 
shows no interfering peaks at retention times of MDZ or its metabolites. 
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Figure 2. Representative HPLC chromatograms of rabbit hepatic microsomes after incubation with MDZ (100 μM) in the 
absence (a) and presence (b) of NADPH.  
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Figure 3: Midazolam plasma concentration-time profile following a single oral administration of 0.075mg/kg midazolam to 
six healthy individuals. 
PHARMACOKINETIC ANALYSIS
The maximum plasma concentration (Cmax) and time to reach 
Cmax (Tmax) following MDZ administration were obtained 
directly from the individual plasma-concentration time data for 
MDZ. The area under concentration-time curve from time zero to 
infinity (AUCo-∞) was measured using linear trapezoidal 
summation with extrapolation.  The terminal elimination rate 
constant (β) was estimated by linear least square regression 
analysis of the terminal log-linear portion of plasma-concentration 
time curve.  The terminal elimination half-life (t1/2 ) was 
determined as ln2/β.
RESULTS
             Intercept           Slope              R2 LLOQ LLOD    Linearity range
Rabbit Hepatic Microsomes Average* SD Average* SD Average* SD  (ng/mL)  (ng/mL)  (ng/mL)
4-OH MDZ 0.0408 0.0059 0.005 0.0004 0.9993 0.00036 10 2.5 10-500
1-OH MDZ 0.0739 0.0014 0.0112 0.0009 0.9995 0.0003 10 2.5 10-500
MDZ 0.0812 0.0052 0.0185 0.0002 0.9994 0.0002 10 2.5 10-500
Human Plasma
MDZ 0.0029 0.0095 0.0196 0.0017 0.9991 0.0009 10 5 10-500
* n = 6
Table 1. Extraction recovery of MDZ, its metabolites and the internal standard (LOR) from spiked rabbit hepatic microsomes (n= 5), 
and extraction recovery of MDZ and LOR in spiked human plasma samples (n = 5).
Table 2. Linearity data for the quantification of MDZ in human plasma and MDZ and its metabolites in rabbit 
hepatic microsomes by the proposed HPLC method.
Cmax Tmax AUC (0-∞) β t1/2
(ng/mL) (hr) (ng.hr/mL) (hr-1) (hr)
Average 1025 0.9167 2031.8333 0.296 2.35
SD (±) 215.1976 0.2041 532.31247 0.024033 0.188
Nominal Conc.               Intra-day (n = 5)                            Inter-day (n = 10)
Analyte (ng/mL) Average SD % Accuracy CV% Average SD % Accuracy CV%
                                     Rabbit Hepatic Microsomes
20 19.03 1.36 95.15 7.2 19.5 1.96 97.5 10.1
4-OH MDZ 100 105.3 6.8 105.3 6.4 106.2 5.7 106.2 5.3
250 265.5 20.2 106.2 7.6 259 19.1 103.6 7.4
20 20.1 2.1 100.5 10.4 20.4 1.97 102 9.6
1-OH MDZ 100 103.2 6.06 103.2 5.9 102.3 5.9 102.3 5.8
250 265.5 20.3 106.2 7.6 255.5 23 102.2 9
20 19.5 1.45 97.5 7.5 20.8 2.1 104 10.2
MDZ 100 103.1 6.7 103.1 6.5 100.5 6.2 100.5 6.2
250 253 15.2 101.2 6 256 18.4 102.4 7.2
                                    Human Plasma
20 20.3 1.9 101.5 9.4 20.2 1.84 101 9.1
MDZ 100 95.3 2.9 95.3 3.1 96.5 3.1 96.5 3.2
250 248.4 16.8 99.36 6.8 252 16.6 100.8 6.7
Table 3. Intraday (n = 5) and inter-day (10 consecutive days) accuracy and precision data for the quantitation of MDZ in 
human plasma, and MDZ and its metabolites in rabbit hepatic microsomes by the proposed HPLC method. 
Table 4: Mean pharmacokinetic parameters of Midazolam following a single-dose (0.075mg/kg) administration of 
midazolam to six healthy individuals.
CONCLUSION
In this study, we describe a new, simple and accurate HPLC-UV method for the simultaneous determination 
of MDZ and it’s metabolites for their drug therapy monitoring and as a surrogate marker for CYP3A enzyme 
activity as well.  This new method offers the advantages of simplicity, accuracy, precision, adequate 
sensitivity, and low sample volume. We successfully applied the method to determine CYP3A activity in 
rabbit hepatic microsomes and to study the pharmacokinetics of MDZ in human plasma.
Minutes
Conc. Recovery (%) CV (% )
Analyte (ng/mL) Average* SD
Rabbit Hepatic Microsomes
20 85.3 5.2 6.1
4-OH MDZ 100 90.8 2.45 2.7
250 90.8 2.56 2.8
20 89.7 2.76 3.1
1-OH MDZ 100 89.08 3.04 3.4
250 89.99 2.68 3.0
20 88.7 1.9 2.1
MDZ 100 90.5 1.17 1.3
250 88.46 5.7 6.4
LOR 20000 89.4 3.65 4.1
Human Plasma
20 89.8 4 4.5
MDZ 100 92.9 2.3 2.5
250 88.6 6.3 7.1
LOR 20000 94.2 12.2 13
* n = 5
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